Oxaprozin NDC 60760-382

NDC codes

FDA NDC Directory

Product NDC (as listed)60760-382Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60760-0382Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60760-382-14	60760038214	14 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60760-382-14)Marketed from Aug 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxaprozin
Generic name (nonproprietary): oxaprozin
Active ingredients: Oxaprozin — 600 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: ST MARY'S MEDICAL PARK PHARMACY
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075855
Marketing start: Aug 15, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)
Identifiers: Product ID 60760-382_5269e91f-7e95-9405-e063-6294a90a3217SPL ID 5269e91f-7e95-9405-e063-6294a90a3217SPL set ID e881dca6-004e-1c3e-e053-2a95a90a02abRxCUI 312132UNII MHJ80W9LRB
Pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460760038214 followed by a unit qualifier and the quantity

Package 60760-0382-14. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 22, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Oxaprozin tablets are indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis Oxaprozin is a non-steroidal anti-inflammatory drug indicated for: Relief of signs and symptoms of Osteoarthritis (OA) (1) Relief of signs and symptoms of Rheumatoid Arthritis (RA) (1) Relief of signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075855

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075855
Product	Strength	Form · route	Labeler	Product NDC
Oxaprozin	Oxaprozin 600 mg/1	Tablet, Film coatedOral	Bryant Ranch Prepack	71335-0393
Oxaprozin	Oxaprozin 600 mg/1	Tablet, Film coatedOral	Dr. Reddy's Laboratories Limited	55111-170
Oxaprozin	Oxaprozin 600 mg/1	Tablet, Film coatedOral	Proficient Rx LP	82804-261
Oxaprozin	Oxaprozin 600 mg/1	Tablet, Film coatedOral	Direct_Rx	72189-595